Explore UAB

Colleges & Schools

Neurofibromatosis Program Heersink School of Medicine
  1. Clinical Management of Plexiform Neurofibromas in the Era of Selumetinib and Other MEK Inhibitor Drugs
  2. Genetic Testing for Schwannomatosis – A Discussion with the Director of the UAB Medical Genomics Laboratory
  3. Marking 40 years of my Involvement in Neurofibromatosis
  4. New Naming Conventions for NF2 and Schwannomatosis Recommended by International Committee of NF Experts
  5. Possible Explanations for the Presence of NF Clinical Features and a Negative Genetic Test
  6. New UAB Multidisciplinary Adult NF Clinic Streamlines Care For Patients with Active Problems
  7. A Discussion with Genetic Scientists Advancing Preclinical Genome-Guided Therapeutics in the UAB NF Research Program
  8. Overview of the UAB NF Clinical Trials Consortium: A Discussion with Members of the Operations Center Administrative Team
  9. The Role of the UAB Medical Genomics Laboratory in NF Patient Care and Research
  10. Physicians Share Insight about Providing Care to Patients in the UAB Pediatric NF Clinic
  11. UAB NF Program Overview and Updates
  12. A Discussion of Genetic Penetrance and Variability of Expression in NF
  13. A Discussion of Malignant Peripheral Nerve Sheath Tumors (MPNSTs)
  14. Expanding Role of Telemedicine in the UAB NF Clinic
  15. A Discussion of Revised Diagnostic Criteria Released for NF1 and Legius Syndrome
  16. Resuming In-Person UAB NF Clinic Visits and a Discussion of the Frequency of NF Clinic Visits for Pediatric and Adult Patients
  17. COVID-19 Issues for Individuals with NF, Highlights of the UAB NF Symposium Family Day, and NF Clinic News
  18. The Difference in Treatment Options for Plexiform Neurofibromas and Malignant Peripheral Nerve Sheath Tumors
  19. A Discussion of RASopathy Disorders and Potential Treatments with Mechanism-Based Therapies
  20. Virtual UAB NF Symposium Family Day Considered for 2021 and a Discussion of Characteristic Brain MRI Findings in NF1
  21. A Discussion of Genotype/Phenotype Correlations in NF1
  22. The Difference in Treatment Options for Plexiform Neurofibromas and Malignant Peripheral Nerve Sheath Tumors
  23. A Discussion of RASopathy Disorders and Potential Treatments with Mechanism-Based Therapies
  24. Virtual UAB NF Symposium Family Day Considered for 2021 and a Discussion of Characteristic Brain MRI Findings in NF1
  25. A Discussion of Genotype/Phenotype Correlations in NF1
  26. FDA Approves Selumetinib as First Treatment for NF1 and a Discussion of MEK Inhibitor-Based Treatments for Plexiform Neurofibromas
  27. Considerations for Individuals with NF Regarding the Novel Coronavirus
  28. The Role of Precision Medicine in NF Diagnosis and Treatment
  29. Highlights from the 2019 NF Conference and ASHG Meeting, Re-Cap of NF Walk, UAB NF Clinic News, and Final Installment of a Review of the Pediatric NF Clinical Care Resource
  30. Upcoming NF Conference and a Review of the Pediatric NF Clinical Care Resource for Neurodevelopmental Problems and Skeletal Abnormalities
  31. UAB NF Symposium Family Day and a Review of Pediatric NF Clinical Care Guidelines for Malignancies and Neurologic Issues Related to NF1
  32. NF Clinic Update and a Review of Pediatric NF Clinical Care Guidelines for Optic Pathway Gliomas and Indications for Neuroimaging in Children with NF1
  33. A Discussion of Newly Published Pediatric NF Clinical Care Guidelines
  34. Approaches to Imaging in the Diagnosis and Management of NF
  35. Explanation of a New Method for Answering NF-Related Email Questions
  36. NF Clinic Adjustments and a Discussion of the Differences Between Schwannomas and Neurofibromas
  37. Multi-Year Research Grants Awarded to UAB Investigators Pursuing Genome-Guided Therapeutics
  38. A Re-Cap of the 2018 NF Conference in Paris
  39. Highlights of Visit with Australian NF Team and Advice for Locating an Experienced NF Program
  40. Upcoming NF Conference and a Final Review of the ACMG Clinical Practice Resource
  41. A Review of ACMG Clinical Practice Resource Related to Hypertension and Vasculopathy, Osteoporosis, and Cutaneous Neurofibromas
  42. A Discussion of ACMG Clinical Practice Resource Related to Tumors Associated with NF1
  43. Highlights of the NF Forum and a Discussion of Newly Published Clinical Care Guidelines for NF1
  44. Highlights of NF Symposium and a Discussion of the Frequency of NF Clinic Visits
  45. A Focus on Improving Our Patients’ Experience and the Relationship Between Atypical Neurofibromas and Malignant Peripheral Nerve Sheath Tumors
  46. New Role as UAB Medicine’s Chief Genomics Officer, Upcoming NF Family Day, and Newly Identified Mutation/Phenotype Correlation in NF
  47. A Re-Cap of the Year’s Endeavors and a Preview of Plans for 2018
  48. Highlights of American Society of Human Genetics Meeting, Alabama NF Walk, and a Discussion of Muscle Involvement in NF1
  49. Recognizing Problems That Require Further Evaluation in Children with NF1
  50. Department of Defense NF Research Program Grant Proposals and a Review of Pain in the Context of NF
  51. Highlights of the 2017 NF Conference, NF Clinical Trials Consortium Update, and Frequently Asked Questions about Clinical Trials
  52. Development of Genome-Guided Therapeutics for NF Based on Genetic Mutation Subsets
  53. Current and Future Research Initiatives for the Treatment of Cutaneous Neurofibromas
  54. Highlights of UAB Rare Disease Genomics Symposium and a Discussion of Visual Screening in Children with NF1
  55. Continued Benefits of NF Clinic Relocations and a Discussion of Headaches in Individuals with NF1
  56. Renewed Grant for the NF Clinical Trials Consortium and a Promising New Drug for the Treatment of NF1
  57. Highlights of a Successful Year and a Look Ahead to New Goals for 2017
  58. Successful Relocation of Adult and Pediatric NF Clinics and a Discussion of Increased Breast Cancer Risk in Women with NF1
  59. A Successful 3rd Annual Alabama NF Walk and a Discussion of Developmental Issues and Cognitive Function in NF1
  60. Highlights of NF Symposium, Plans for 3rd Annual NF Walk, Discussion of Mosaic NF1, and a Review of the NF Neurologic Exam
  61. Upcoming NF Symposium at Children’s Harbor, Applications of New Gene Editing Technology, and a Review of the NF Extremities Exam
  62. NF Clinic Genetics Counselor Receives Esteemed Scholars Award, Re-Cap of NF Forum, and What to Expect During an NF Genital Exam
  63. Upcoming NF Symposium, Enhanced Patient Exam Procedure, and a Review of the NF Abdominal Exam
  64. Sources of Variability in NF and What to Expect During an NF Chest Examination
  65. Re-Cap of Meetings in Washington, DC, for Renewed NF Research Funding and a Review of What to Expect During an NF Neck Exam
  66. New Discoveries in the UAB Medical Genomics Laboratory, Animal Model Progress, and NF-Related Features of the Head
  67. New Year’s Resolutions for the NF Program and Common Skin Issues Detected During an NF Clinic Visit
  68. Animal Model Research Update, Plans for Adult and Pediatric NF Clinics, and the Focus of Exams in an NF Clinic
  69. Successful 2nd Annual Alabama NF Walk and Update on Newly Formed NF Community Advisory Board
  70. Upcoming 2nd Annual Alabama NF Walk and Understanding the Role of NF Genetic Testing
  71. A Successful and Memorable NF Family Day and Plans for Future Dermal Neurofibroma Trials
  72. A New Specialist Joins the NF Clinic Team, Upcoming NF Symposium at UAB, and Understanding RAS Disorders and their Relationship to NF
  73. Understanding Possible Explanations for Isolated Features of NF
  74. Responding to E-mailed Questions from Patients and Reviewing Diagnostic Criteria for Café-Au-Lait Spots and Groin Freckling
  75. Measurement Technique for Dermal Neurofibromas Validated at UAB Expands Possibilities for Clinical Trials
  76. Birmingham Family Affected by NF Recognized at CTF BeNeFit II Gala in Detroit, and Frequently Asked Patient Questions Regarding NF Clinical Trials
  77. Highlights of NF Family Day and Encouraging Developments from an International NF Meeting
  78. Upcoming NF Family Day, Research Advances, and a Special Award for a Birmingham Family Affected by NF
  79. A Successful NF Walk, Two Key NF Conferences, and Rapid Research Progress
  80. A new website and Birmingham's first NF walk